Martindale Pharma, the UK-based leading international specialty pharmaceutical company, has announced the relaunch of its methadone oral solution product in Scandinavia via its strategic partner Unimedic AB.
Martindale Pharma’s methadone oral solution will be available for prescribers from 1 April 2016 in Norway and Sweden and 1 May 2016 in Finland.
Martindale Methadone Oral Solution represents a novel option for patients requiring opioid substitution therapy (OST) for the treatment of opioid addiction. The product is a 2 mg/mL, orange flavoured, sugar-free oral liquid and has been noted by prescribers and patients as the preferred treatment solution as existing products can contain large amounts of sugar/other flavours or unwanted additives such as alcohol. The product comes in a range of small volumes where one bottle can be used as a single dose.
The relaunch of the product follows a change in excipients used in the formulation as well as the new appointment of Unimedic AB, as Martindale Pharma’s partner for this product range in Scandinavia. This partnership expands a successfully established relationship with Unimedic AB for the marketing of Martindale Pharma’s sterile injection products.
Commenting on the launch Michael Harris, CEO of Martingale Pharma, said: “We are very pleased to expand our portfolio of opioid addiction treatments by the reintroduction of this methadone product into Scandinavia. Martindale Pharma’s comprehensive range of methadone products have been formulated to meet multiple patient, pharmacists and prescriber needs and the relaunch of this product marks our on-going commitment to providing patients with safe and effective treatments.”
“Our experience and breadth of product portfolio make us a market leader and highly trusted supplier of opioid addiction products in the UK and Scandinavia, and we are actively seeking to expand our commercial agreements in Europe for this part of our business,” he added.